MindMed (MMED) issues an MM120 clinical or corporate disclosure within 8 weeks that explains today's divergent move.

MindMed's stock moved up 4.5% on its own, without any broader market reason, which often means insiders or informed traders are buying ahead of news. The company's drug MM120 — a carefully refined version of LSD being tested for generalized anxiety disorder — is at a stage in its clinical testing where results could drop soon. An announcement of some kind is expected within about two months.

A 4.5% idiosyncratic move on a quiet tape front-runs information. MM120 GAD readout cadence fits the window. The narrative is noise; the price action isn't.